No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FMX240816P110000
- 1.00
- 0.000.00%
15min DelayClose Jul 15 10:03 ET
0.00High0.00Low
0.00Open1.00Pre Close0 Volume0 Open Interest110.00Strike Price0.00Turnover33.93%IV8.27%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry1.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1704Delta0.0241Gamma118.83Leverage Ratio-0.0510Theta-0.0129Rho-20.25Eff Leverage0.0786Vega
Intraday
- 5D
- Daily
News
Coca-Cola FEMSA Extends Post-earnings Gain
Earnings Call: Coca-Cola FEMSA Reports Robust Growth Amidst Challenges
Coca Cola Femsa SAB De CV (KOF) Gets a Buy From Barclays
Coca-Cola FEMSA, S.A.B. De C.V. (KOF) Q2 2024 Earnings Call Transcript
Coca-Cola FEMSA, S.A.B. de C.V. (KOF) Q2 2024 Earnings Call Transcript
Coca-Cola FEMSA Shares Rise After Q2 Results
Coca-Cola FEMSA (KOF) shares were up nearly 2% in recent Friday trading after the company reported its Q2 results.Coca-Cola FEMSA reported Q2 earnings Friday of 2.67 Mexican pesos ($0.15) per unit.
Coca-Cola FEMSA GAAP EPS of Ps. 0.33
Comments
FEMSA's CEO expressed satisfaction with strong Q4 results, robust revenue growth across units, and Coca-Cola FEMSA's performance. He also discussed the impact of increased labor costs and the strategic plan to reach leverage objectives.
Press Release: FEMSA Announces Fourth Quarter and Full Year 2023 ResultsFEMSA's CEO highlighted robust performance, expressed confidence in organic growth especially in Proximity Americas and Coca-Cola FEMSA. Despite stability, expects solid growth in Health revenues and significant core business investment.
Upgrades
• $Blueprint Medicines(BPMC.US$ : Jefferies Upgrades to Buy from Hold - PT $78 (from $88)
• $CatchMark Timber Trust Inc(CTT.US$ : Raymond James Upgrades to Market Perform from Underperform
• $Danaher(DHR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $310 (from $299)
• $Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to In Line from Underperform - PT $39 (from $35)
• $FEMSA(FMX.US$ : Bradesco BBI Upgrades to Outperform f...
• $Blueprint Medicines(BPMC.US$ : Jefferies Upgrades to Buy from Hold - PT $78 (from $88)
• $CatchMark Timber Trust Inc(CTT.US$ : Raymond James Upgrades to Market Perform from Underperform
• $Danaher(DHR.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $310 (from $299)
• $Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to In Line from Underperform - PT $39 (from $35)
• $FEMSA(FMX.US$ : Bradesco BBI Upgrades to Outperform f...
10
2
Upgrades
• $AGNC Investment Corp(AGNC.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $13 (from $13.50)
• $Esperion Therapeutics(ESPR.US$ : JP Morgan Upgrades to Neutral From Underweight
• $Fortinet(FTNT.US$ : Mizuho Securities Upgrades to Buy from Neutral - PT $350 (from $340)
• $Horizon Technology Finance(HRZN.US$ : Compass Point Upgrades to Neutral From Sell
• $Momentive Global(MNTV.US$ : Craig-Hallum Upgrades to Buy from Hold - PT $...
• $AGNC Investment Corp(AGNC.US$ : Piper Sandler Upgrades to Overweight from Neutral - PT $13 (from $13.50)
• $Esperion Therapeutics(ESPR.US$ : JP Morgan Upgrades to Neutral From Underweight
• $Fortinet(FTNT.US$ : Mizuho Securities Upgrades to Buy from Neutral - PT $350 (from $340)
• $Horizon Technology Finance(HRZN.US$ : Compass Point Upgrades to Neutral From Sell
• $Momentive Global(MNTV.US$ : Craig-Hallum Upgrades to Buy from Hold - PT $...
15
Read more